BioCardia Advances CardiAMP Regulatory Pathways in Japan and U.S.
Event summary
- BioCardia received positive regulatory feedback from Japan’s PMDA and the U.S. FDA on its CardiAMP Cell Therapy.
- The company plans to submit a Shonin application in Japan by Q4 2026.
- Net loss decreased to $1.6 million for Q2 2026, down from $2.0 million in Q2 2025.
- BioCardia raised $4.9 million under its At-the-Market facility during the quarter.
The big picture
BioCardia’s strategic focus on regulatory pathways in Japan and the U.S. reflects a broader industry trend of biotech companies seeking parallel approvals to accelerate market entry. The company’s efficient use of capital, despite operating losses, positions it for potential partnerships or licensing deals as it advances its cardiovascular therapies.
What we're watching
- Regulatory Timelines
- The pace at which BioCardia can address PMDA’s requests and finalize its submission in Japan.
- Clinical Enrollment
- Whether the ongoing CardiAMP HF II trial can meet enrollment targets to support FDA approval.
- Strategic Partnerships
- How BioCardia’s business development efforts around its cell therapies and delivery technologies will progress.
Related topics